CD
CDXI.US Cardax Inc
- Market cap
- USD 80.00
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is CDXI.US undervalued?
Graham numberThe Graham number of Cardax Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cardax Inc fundamental analysis
No fundamental analysis for Cardax Inc yet.
Cardax Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cardax Inc
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical …
Full company profileCardax Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cardax Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 35.3K | 610K | 1.51M | 711K | 539K | - | - | - |
| Gross Profit | - | 0.00 | -4.40M | 20.7K | 336K | 811K | 366K | 343K | - | - | - |
| Operating Income | -4.36M | -16.9M | -4.40M | -1.83M | -2.00M | -4.02M | -4.08M | -3.06M | - | - | - |
| EBITDA | - | -16.8M | -4.23M | -1.75M | -1.97M | -3.99M | -4.43M | -2.64M | - | - | - |
| Net Income | -5.13M | -17.0M | -4.26M | -1.78M | -1.99M | -4.02M | -5.09M | -5.06M | - | - | - |
| EPS | -0.54 | -56 | -13 | -4.68 | -3.97 | -6.32 | -7.49 | -6.79 | - | - | - |
| Balance Sheet | |||||||||||
| Total Assets | 1.77M | 1.55M | 852K | 751K | 3.16M | 2.46M | 2.02M | 1.43M | - | - | 1.38M |
| Total Liabilities | 14.7M | 4.76M | 4.60M | 4.64M | 4.56M | 5.99M | 9.22M | 11.6M | - | - | 12.7M |
| Shareholders' Equity | -12.9M | -3.21M | -3.75M | -3.89M | -1.41M | -3.54M | -7.20M | -10.2M | - | - | -11.4M |
| Cash & Short-term Investments | 222K | 35.7K | 323K | 158K | 2.24M | 244K | 19.3K | 19.2K | - | - | 58.7K |
| Total Debt | - | - | - | - | - | - | 2.60M | 4.78M | - | - | 5.40M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.13M | -5.70M | -1.51M | -1.26M | -2.08M | -3.20M | -3.52M | -1.79M | - | - | - |
| Capital Expenditure | 30.3K | 28.3K | 22.0K | 29.2K | 19.4K | 36.6K | 61.6K | 14.6K | 0.00 | - | - |
| Free Cash Flow | - | -5.72M | -1.53M | -1.29M | -2.10M | -3.24M | -3.58M | -1.81M | - | - | - |
| Ratios | |||||||||||
| ROA | -290.1% | -1,098.5% | -499.7% | -237.6% | -62.9% | -163.7% | -252.3% | -354.7% | - | - | - |
| Net Profit Margin | - | - | - | -5,059.0% | -325.3% | -266.4% | -716.4% | -938.0% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cardax Inc dividends
Cardax Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:200 on Jan 15, 2020.
Who owns Cardax Inc
- Insiders 0.00%
- Institutions 0.01%
- Public & others 99.99%
- Shares outstanding 803K
- Free float 590K
Cardax Inc company profile
- Company name
- Cardax Inc
- Ticker
- CDXI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 10
- Fiscal year end
- December
- Address
- 2800 Woodlawn Drive, Honolulu, HI, United States, 96822
- Phone
- 808 457 1400
- Website
- cardaxpharma.com
About Cardax Inc
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.
Cardax Inc management
3- Mr. David G. WatumullChairman & CEO · born 1950
- Mr. David M. WatumullCOO & CFO · born 1982
- Mr. Gilbert ShinVice President of Retail Sales & Marketing